CADL - Company ID 0001841387
The table below shows Candel Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$18.04M | -$8.62M | -$8.44M | -$10.82M | -$8.05M | -$5.63M |
| Capital expenditure | $675.00K | $3.00K | $7.00K | $138.00K | $171.00K | $229.00K |
| Investing cash flow | -$675.00K | -$3.00K | -$7.00K | $19.00K | -$171.00K | -$229.00K |
| Dividends paid | - | - | - |
Candel Therapeutics, Inc. reported operating cash flow of -$38.31M for fiscal year 2025. That is down 41.8% from -$27.02M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$9.07M (FY 2020) to -$38.31M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $93.81M | -$1.87M | -$1.25M | $0.00 | $19.92M | $112.00K |